期刊
NEUROPSYCHIATRY
卷 1, 期 5, 页码 441-455出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NPY.11.49
关键词
-
资金
- Agency for Healthcare Research and Quality (AHRQ)
- Corcept Therapeutics, Inc.
- Cyberonics, Inc.
- Merck
- National Alliance for Research in Schizophrenia and Depression
- National Institute of Mental Health
- National Institute on Drug Abuse
- Novartis
- Pharmacia Upjohn
- Predix Pharmaceuticals (Epix)
- Solvay Pharmaceuticals, Inc.
- Targacept
- Abbott Laboratories, Inc.
- Abdi Ibrahim
- Akzo (Organon Pharmaceuticals, Inc.)
- AstraZeneca
- Bristol-Myers Squibb Company
- Cephalon, Inc.
- Evotec
- Fabre Kramer Pharmaceuticals, Inc.
- Forest Pharmaceuticals
- GlaxoSmithKline
- Janssen Pharmaceutica Products
- LP
- Johnson Johnson PRD
- Eli Lilly Company
- Meade Johnson
- Medtronic
- Neuronetics
- Otsuka Pharmaceuticals
- Parke-Davis Pharmaceuticals, Inc.
- Pfizer Inc.
- Sepracor
- SHIRE Development
- VantagePoint
- Wyeth-Ayerst Laboratories
Major depressive disorder (MDD) and metabolic syndrome (MetS) are both widespread and cause enormous morbidity. The presence of one syndrome approximately doubles the risk of the other. Standard antidepressant treatments lead to remission in less than a third of the patients; a majority of patients experience treatment resistance at some point during their illness. Research focusing on clinical and biological markers has yet to provide evidence for the cause(s) of treatment resistance. MDD and MetS share endocrine and immune abnormalities that account for their overlap and suggest potential mechanisms for treatment resistance for a subgroup of patients with MDD. Cortisol resistance and positive energy balance work together to create inflammation. Chronic inflammation leads to insulin resistance. In the brain, inflammation and insulin resistance cause changes in metabolic control, decreases in serotonin synthesis, decreased hedonic drive and lower hippocampal neurogenesis, all of which are consistent with the neurobiology of MDD. We hypothesize that treatment-resistant MDD may result when MetS reinforces the pathophysiology of MDD, making it harder to reverse.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据